GABARNANCE Trial
Borderline resectable pancreatic cancer (BRPC) is a tumor that is in certain level contact with the surrounding major blood vessels and often has a poor prognosis with positive surgical margins after resection. Although it is known that preoperative treatment is effective for borderline pancreatic cancer, the standard of care is not yet known.
The GABARNANCE trial is a multicenter, randomized phase II/III trial that aims to establish the standard of care for borderline pancreatic cancer. This website introduces the GABARNANCE trial.
Official Title of the study
Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer - GABARNANCE Trial
CONTACT
For inquiries about participation in research
National Cancer Center Hospital East
Medical Device Project Management Office / Hepato-Biliary Pancreatic Surgery Division
Shinichiro Takahashi
TEL: +81-4-7133-1111
FAX: +81-4-7131-4724
Inquiries about the study from participating facilities (central imaging support, eligibility criteria, treatment change criteria, etc.)
National Cancer Center Hospital East
Hepato-Biliary Pancreatic Oncology
Masafumi Ikeda
TEL: +81-4-7133-1111
FAX: +81-4-7133-0335
